MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 126.1 USD | -2.63% |
|
-3.57% | +15.66% |
| 03:26am | Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports | RE |
| 03:09am | Merck Nears $1.3 Billion Deal For Eye-Drug Company Eyebio - WSJ | RE |
Financials (USD)
| Sales 2024 * | 64.13B | Sales 2025 * | 68.61B | Capitalization | 319B |
|---|---|---|---|---|---|
| Net income 2024 * | 19.51B | Net income 2025 * | 22.25B | EV / Sales 2024 * | 5.27 x |
| Net Debt 2024 * | 18.6B | Net Debt 2025 * | 7.29B | EV / Sales 2025 * | 4.76 x |
| P/E ratio 2024 * |
16.3
x | P/E ratio 2025 * |
14.1
x | Employees | 71,000 |
| Yield 2024 * |
2.45% | Yield 2025 * |
2.6% | Free-Float | 70.77% |
More Fundamentals
* Assessed data
More news
Latest transcript on Merck & Co., Inc.
More recommendations
More press releases
More news
| 1 day | -2.63% | ||
| 1 week | -3.57% | ||
| Current month | -2.42% | ||
| 1 month | -3.89% | ||
| 3 months | -1.64% | ||
| 6 months | +25.86% | ||
| Current year | +15.66% |
1 week
125.74
131.92
1 month
125.74132.79
Current year
109.16133.10
1 year
99.14133.10
3 years
70.89133.10
5 years
65.25133.10
10 years
45.69133.10
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 14-03-31 |
| Director of Finance/CFO | 55 | 89-12-31 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 07-11-26 |
Pamela Craig
BRD | Director/Board Member | 67 | 15-08-31 |
Inge Thulin
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 14.34% | 254 M€ | +12.51% | - | |
| 5.61% | 17 M€ | +7.15% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 126.1 | -2.63% | 10,263,383 |
| 24-05-24 | 129.5 | -1.22% | 5,983,846 |
| 24-05-23 | 131.1 | -0.01% | 6,830,987 |
| 24-05-22 | 131.1 | +0.26% | 4,407,644 |
| 24-05-21 | 130.8 | -0.18% | 6,254,679 |
Delayed Quote Nyse, May 28, 2024 at 04:00 pm EDT
More quotes
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
126.1
USD
Average target price
141.9
USD
Spread / Average Target
+12.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.66% | 319B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +0.24% | 274B | |
| +14.04% | 238B | |
| +6.98% | 204B | |
| -6.75% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B | |
| -1.43% | 120B |
- Stock Market
- Equities
- MRK Stock
